Novo Nordisk A/S (NVO.N)
27 Nov 2015
* Announces nanobody drug discovery collaboration with Novo Nordisk A/S
* Says data showed Saxenda treatment in combination with a reduced-calorie diet and increased physical activity demonstrated significant and sustained weight loss over three years compared with placebo
LONDON Novo Nordisk is considering options ahead of key heart safety data for its diabetes drug Victoza and could run a further clinical study if necessary, the Danish company's research head said on Wednesday.
* Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Denmark, creating 450 new jobs
LONDON, Oct 30 Europe's earnings season is nearing the halfway point but already a batch of profit warnings and some disappointing results are souring hopes for the kind of slam-dunk earnings recovery that would support a share rally.
* Novo expects sales and operating profit to grow 5-9 pct in 2016
COPENHAGEN, Oct 29 Denmark's Novo Nordisk said on Thursday it saw mid to high single-digit percent growth in operating profit in local currencies next year, outlining its preliminary forecasts for 2016.
LONDON AstraZeneca opened a new $224 million drug manufacturing and packaging factory in Russia on Tuesday in a move Chief Executive Pascal Soriot said reinforced its long-term commitment to the country.
LONDON, Oct 20 AstraZeneca opened a new $224 million drug manufacturing and packaging factory in Russia on Tuesday in a move Chief Executive Pascal Soriot said reinforced its long-term commitment to the country.
COPENHAGEN Shares in Novo Nordisk rose as much as 5 percent on Monday after the U.S. Food and Drug Administration (FDA) approved the diabetes drug Tresiba, allowing the Danish drugmaker to prepare its largest ever drug launch.